A Real-world Observational Study on the Efficacy and Safety of Anti HER2 Therapy
Latest Information Update: 12 Sep 2023
At a glance
- Drugs Lapatinib (Primary) ; Neratinib (Primary) ; Pertuzumab (Primary) ; Pyrotinib (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Trastuzumab-deruxtecan (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 06 Sep 2023 Status changed from recruiting to completed.
- 17 May 2022 New trial record